Characterization of Treatment-Naive HIV/HBV Co-Infected Patients Attending ART Clinic of a Tertiary Healthcare Centre in Eastern India

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Saha, Debraj ^a   Pal, Ananya ^a   Biswas, Avik ^a   Panigrahi, Rajesh ^a   Sarkar, Neelakshi ^a   Sarkar, Jayeeta ^b   Pal, Manisha ^d   Guha, Subhasish Kamal ^b   Saha, Bibhuti ^b   Chakrabarti, Sekhar ^c   Chakravarty, Runu ^a  

^a INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

^b CALCUTTA SCHOOL OF TROPICAL MEDICINE   (India)

^c NATIONAL INSTITUTE OF CHOLERA AND ENTERIC DISEASES   (India)

^d UNIVERSITY OF CALCUTTA   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; HEPATITIS C ANTIBODY; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; VIRUS DNA;

ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; DNA DETERMINATION; EARLY INTERVENTION; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NUCLEOTIDE SEQUENCE; OUTPATIENT DEPARTMENT; POLYMERASE CHAIN REACTION; PREVALENCE; TERTIARY HEALTH CARE; VIRUS LOAD; VIRUS MUTATION;

ADOLESCENT; ADULT; AGED; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COINFECTION; DNA, VIRAL; FEMALE; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; INDIA; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; TERTIARY HEALTHCARE; VIREMIA; YOUNG ADULT;

EID: 84883408916     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073613     Document Type: Article

References (39)

1. Alter MJ, (2006) Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44: S6-S9.
2. Sellier P, Schnepf N, Jarrin I, Mazeron MC, Simoneau G, et al. (2010) Description of liver disease in a cohort of HIV/HBV coinfected patients. J Clin Virol 47: 13-17.
3. Soriano V, Vispo E, Labarga P, Medrano J, Barreiro P, (2010) Viral hepatitis and HIV co-infection. Antiviral Res 85: 303-315.
4. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, et al. (2006) Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 166: 1632-1641.
5. Koziel MJ, Peters MG, (2007) Viral hepatitis in HIV infection. N Engl J Med 356: 1445-1454.
6. National AIDS Control Organization (NACO) (2012) NACO Annual Report 2011-2012. Available: http://www.aidsdatahub.org/dmdocuments/NACO_Annual_Report_2011_12. pdf. Accessed 18 February 2013.
7. Biswas A, Banerjee A, Chandra PK, Datta S, Panigrahi R, et al. (2011) Variations in the functional domain of basal core promoter of Hepatitis B virus among eastern Indian patients with prevalence of genotypes A, C, and D among the same ethnic population. J Med Virol 83: 253-260.
8. Chandra PK, Banerjee A, Datta S, Chakravarty R, (2007) G1862T mutation among hepatitis B virus-infected individuals: association with viral genotypes and disease outcome in Kolkata, Eastern India. Intervirology 50: 173-180.
9. Kwok S, Higuchi R, (1989) Avoiding false positives with PCR. Nature 339: 237-238.
10. Biswas A, Chandra PK, Datta S, Panigrahi R, Banerjee A, et al. (2009) Frequency and distribution of hepatitis B virus genotypes among eastern Indian voluntary blood donors: Association with precore and basal core promoter mutations. Hepatol Res 39(1): 53-59.
11. Pal A, Panigrahi R, Biswas A, Datta S, Sarkar N, et al. (2013) Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients. Virology 436 (1): 134-142.
12. Corbet S, Bukh J, Heinsen A, Fomgaard A, (2003) Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol 41(3): 1091-1100.
13. Acharya SK, Madan K, Dattagupta S, Panda SK, (2006) Viral hepatitis in India. Natl Med J India 19 (4): 203-217.
14. Yan YX, Gao YQ, Sun X, Wang W, Huang XJ, et al. (2011) Prevalence of hepatitis C virus and hepatitis B virus infections in HIV-positive Chinese patients. Epidemiol Infect 139: 354-360.
15. Saha MK, Chakrabarti S, Panda S, Naik TN, Manna B, et al. (2000) Prevalence of HCV and HBV infection amongst HIV seropositive intravenous drug users and their non-injecting wives in Manipur, India. Indian J Med Res 111: 37-39.
16. Datta S, Banerjee A, Chandra PK, Mahapatra PK, Chakrabarti S, et al. (2006) Drug trafficking routes and hepatitis B in injection drug users, Manipur, India. Emerg Infect Dis 12(12): 1954-1957.
17. Chelleng PK, Borkakoty BJ, Chetia M, Das HK, Mahanta J, (2008) Risk of hepatitis C infection among injection drug users in Mizoram, India. Indian J Med Res 128(5): 640-646.
18. Gupta S, Singh S, (2010) Occult hepatitis B virus infection in ART-naive HIV-infected patients seen at a tertiary care centre in north India. BMC Infect Dis 10: 53.
19. Panigrahi R, Biswas A, Datta S, Banerjee A, Chandra PK, et al. (2010) Anti-hepatitis B core antigen testing with detection and characterization of occult hepatitis B virus by an in-house nucleic acid testing among blood donors in Behrampur, Ganjam, Orissa in southeastern India: implications for transfusion. Virol J 7: 204.
20. Banerjee A, Datta S, Chandra PK, Roychowdhury S, Panda CK, et al. (2006) Distribution of hepatitis B virus genotypes: phylogenetic analysis and virological characteristics of genotype C circulating among HBV carriers in Kolkata, Eastern India. World J Gastroenterol 12(37): 5964-5971.
21. Gandhe SS, Chadha MS, Arankalle VA, (2003) Hepatitis B virus genotypes and serotypes in western India: lack of clinical significance. J Med Virol 69(3): 324-330.
22. Vivekanandan P, Abraham P, Sridharan G, Chandy G, Daniel D, et al. (2004) Distribution of hepatitis B virus genotypes in blood donors and chronically infected patients in a tertiary care hospital in southern India. Clin Infect Dis 38(9): e81-86.
23. Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, et al. (2007) Hepatitis B Virus Co-Infection Impacts Baseline HIV parameters and HAART-related Hepatotoxicity Risk in an HIV-infected Nigerian Cohort. Clin Infect Dis 49(8): 1268-1273.
24. Jobarteh M, Malfroy M, Peterson I, Jeng A, Sarge-Njie R, et al. (2010) Seroprevalence of hepatitis B and C virus in HIV-1 and HIV-2 infected Gambians. Virol J 7: 230.
25. Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, et al. (2010) Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 65(3): 548-555.
26. Thio CL, Smeaton L, Saulynas M, Hwang H, Saravan S, et al. (2013) Characterization of HIV-HBV coinfection in a multinational HIV-infected cohort. AIDS 27(2): 191-201.
27. Lok AS, McMahon BJ, (2009) Chronic hepatitis B: update. Hepatology 50(3): 661-662.
28. Banerjee A, Banerjee S, Chowdhury A, Santra A, Chowdhury S, et al. (2005) Nucleic acid sequence analysis of BCP/precore/core region of hepatitis B virus isolated from chronic carriers of the virus from Kolkata, Eastern India: Low frequency of mutation in the precore region. Intervirology 48: 389-399.
29. Chauhan R, Kazim SN, Bhattacharjee J, Sakhuja P, Sarin SK, (2006) Basal core promoter, precore region mutations of HBV and their association with e antigen, genotype, and severity of liver disease in patients with chronic hepatitis B in India. J Med Virol 78: 1047-1054.
30. Neuschwander-Tetri BA, Caldwell SH, (2003) Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37(5): 1202-1219.
31. Iser DM, Sharon LR, (2009) Future directions in the treatment of HIV-HBV coinfection. HIV Ther 3(4): 405-415.
32. Locarnini S, (2008) Primary resistance, multidrug resistance and cross-resistance pathways in HBV as consequence of treatment failure. Hepatol Int 2(2): 147-151.
33. Sheldon J, Soriano V, (2008) Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 61: 766-768.
34. Clements CJ, Coghlan B, Creti M, Locarnini S, Tedder R, et al. (2010) Global control of HBV: does treatment-induced antigenic change affect immunization? Bull World Health Organ 88: 66-73.
35. Thibault V, Aubron-Olivier C, Agut H, Katlama C, (2002) Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 16: 131-133.
36. Trevino A, Soriano V, Madejon A, Rodriguez C, Barros C, et al. (2009) Transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. AIDS Res Hum Retroviruses 25: 1273-1276.
37. Tuma P, Pineda JA, Labarga P, Vidal F, Rodriguez C, et al. (2011) HBV primary drug resistance in newly diagnosed HIV/HBV co-infected individuals in Spain. Antivir Ther 16(4): 585-589.
38. Rockstroh JK, Bhagani S, Benhamou Y, Bruno R, Mauss S, et al. (2008) European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C co-infection in HIV infected adults. HIV Med 9: 82-88.
39. de Vries-Sluijs TE, Reijnders JG, Hansen BE, Zaaijer HL, Prins JM, et al. (2010) Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus. Gastroenterology 139: 1934-1941.